Bone and joint disease
Conditions
Interventions
Group A:Prophylactic use of ondansetron oral film is not used preoperatively.
Group B:16 mg of ondansetron oral dissolution membrane will be administered orally 1 hour before anesthesia induction.
Group C:16mg orally 1 hour before induction of anesthesia + 8mg orally 8 hours after induction of anesthesia.
Group D:8mg orally 1 hour before anesthesia induction.
Group E:8mg orally 1 hour before induction of anesthesia + 8mg orally 8 hours after induction of anesthesia.
Group F:8mg orally 1 hour before induction of anesthesia + 8mg orally 8 hours after induction of anesthesia + 8mg orally 16 hours after induction of anesthesia.
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients aged between 18 and 80 years underwent primary, unilateral hip-knee replacement for end-stage hip-knee disease.
Exclusion criteria
Exclusion criteria: (1) Ondansetron allergy; (2) Systemic use of steroids and antiemetics within 24 hours before surgery; (3) History of steroid or immunosuppressive drug use within 6 months prior to surgery; (4) A history of gastrointestinal disease, such as reflux esophagitis, gastroduodenal ulcer, or severe impairment of gastrointestinal motility; (5) Poor perioperative blood sugar and blood pressure control; (6) Combined with Meniere syndrome and other diseases that may cause nausea and vomiting; (6) Patients who are participating in other clinical studies or who are expected to have insufficient compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency and intensity of nausea;Frequency of vomiting; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions related to drug use; | — |
Countries
China
Contacts
Public ContactWang Haoyang
West China Hospital of Sichuan University
Outcome results
None listed